Publication

HDL (High-Density Lipoprotein) Cholesterol Efflux Capacity Is Associated With Incident Cardiovascular Disease in the General Population A Case-Control Study From the PREVEND Cohort

Ebtehaj, S., Gruppen, E. G., Bakker, S. J. L., Dullaart, R. P. F. & Tietge, U. J. F., Sep-2019, In : Arteriosclerosis thrombosis and vascular biology. 39, 9, p. 1874-1883 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • HDL (High-Density Lipoprotein) Cholesterol Efflux Capacity Is Associated With Incident Cardiovascular Disease in the General Population

    Final publisher's version, 222 KB, PDF document

DOI

Objective: Focus is shifting from HDL-C (high-density lipoprotein cholesterol) as predictive biomarker for cardiovascular disease (CVD) towards antiatherogenic HDL functionalities. Still, limited data exist on the prospective association of HDL function metrics with CVD events. The current work aimed to determine, if baseline HDL-C efflux capacity (CEC) is associated with future CVD events in the general population. Approach and Results: We performed a prospective study among participants of the PREVEND (Prevention of Renal and Vascular End-stage Disease) cohort (follow-up, 12 years). From the overall n=8592 subjects 325 with previous CVD events were excluded; of the remaining 8267 eligible participants all subjects with new CVD events during follow-up were selected and individually matched to controls for age, sex, smoking status, and HDL-C levels. CEC at baseline was quantified using human THP-1-derived macrophage foam cells and apolipoprotein B-depleted plasma. Despite identical HDL-C and apoA (apolipoprotein)-I levels between cases (n=351) and controls (n=354) CEC was significantly lower in cases (0.93 +/- 0.29 versus 1.01 +/- 0.24 arbitrary units; P

Original languageEnglish
Pages (from-to)1874-1883
Number of pages10
JournalArteriosclerosis thrombosis and vascular biology
Volume39
Issue number9
Publication statusPublished - Sep-2019

    Keywords

  • albumins, atherosclerosis, biomarker, cardiovascular disease, foam cells, urinary albumin excretion, RISK, EVENTS, PLASMA, MORTALITY, SERUM

ID: 98080886